Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07749664 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients

Study acronym: DEL1-DN
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Aswan University
27 trials monitored
See 1 trial at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression. Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction. This study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity. This observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.
Trial Details
NCT Number NCT07749664
Lead Sponsor Aswan University
Conditions
(from sponsor)		 Nephropathy, Diabetic
Related terms Diabetic Nephropathies
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov